57 scientists and doctors call for immediate stop of all Covid-19 “vaccinations”
By Ziinine A. Britshi
MalaysiaWorldNews
A group of 57 leading scientists, doctors and political experts have released a report questioning the safety and efficacy of current COVID-19 ” vaccines “, and are now calling for an immediate stop to all vaccination programs, A French blog FranceSoir reported.
Among 57 scientists is the geneticist Alexandra Henrion-Caude, from French Institute of Health and Medical Research | Inserm · Unit of Genetics and Epigenetics of Neurometabolic Diseases and Birth Defects
Director of Research, Inserm, the report said.
The “vaccines”, they said, do not meet the definition of the word vaccine and it would be more appropriate to call them “gene therapy” or “vaccine vector therapy .”
There are two certainties regarding the global distribution of these Covid-19 therapies:
The first is that governments and the vast majority of mainstream media are working hard to make these investigational drugs available to as many people as possible.
The second is that those who are prepared to face the contempt that comes with asking serious questions about vaccines are essential players in our ongoing efforts to spread the truth.
The group of scientists have also release pre-print manuscript on the net and asking people to read it.
The manuscript has been prepared by nearly sixty doctors, scientists and public policy experts around the world to be sent urgently to world leaders, as well as to all those associated with the production and distribution of the various Covid-19 vaccines.
There are still far too many unanswered questions regarding the safety , efficacy and necessity of these Covid-19 therapies, they claim, adding that there are not enough citizens asking questions. Most people just follow the orders of world governments, as if they’ve earned our full trust.
Read the manuscript here: https://www.francesoir.fr/societe-sante/57-scientifiques-et-medecins-demandent-larret-immediat-de-toutes-les-vaccinations#.YJjg6cXUI0p.whatsapp
Below is the translation of this French manuscript:
Mass vaccination against SARS-CoV-2: urgent vaccine safety questions that demand answers from international health agencies, regulatory authorities, governments and vaccine developers
Authors: Roxana Bruno (1), Peter McCullough (2), Teresa Forcades i Vila (3), Alexandra Henrion-Caude (4), Teresa García-Gasca (5), Galina P. Zaitzeva (6), Sally Priester (7 ), María J. Martínez Albarracín (8), Alejandro Sousa-Escandon (9), Fernando López Mirones (10), Bartomeu Payeras Cifre (11), Almudena Zaragoza Velilla (10), Leopoldo M. Borini () 1, Mario Mas (1), Ramiro Salazar (1), Edgardo Schinder (1), Eduardo A Yahbes (1), Marcela Witt (1), Mariana Salmeron (1), Patricia Fernández (1), Miriam M. Marchesini (1), Alberto J. Kajihara (1), Marisol V. de la Riva (1), Patricia J. Chimeno (1), Paola A. Grellet (1), Matelda Lisdero (1), Pamela Mas (1), Abelardo J. Gatica Baudo (12), Elisabeth Retamoza (12), Oscar Botta (13), Chinda C. Brandolino (13), Javier Sciuto (14), Mario Cabrera Avivar (14),Mauricio Castillo (15), Patricio Villarroel (15), Emilia P. Poblete Rojas (15), Bárbara Aguayo (15), Dan I. Macías Flores (15), Jose V. Rossell (16), Julio C. Sarmiento (17 ), Victor Andrade-Sotomayor (17), Wilfredo R. Stokes Baltazar (18), Virna Cedeño Escobar (19), Ulises Arrúa (20), Atilio Farina del Río (21), Tatiana Campos Esquivel (22), Patricia Callisperis ( 23), María Eugenia Barrientos (24), Karina Acevedo-Whitehouse (5),Karina Acevedo-Whitehouse (5),Karina Acevedo-Whitehouse (5),
Summary
Since the start of the COVID-19 epidemic, the race to test new platforms designed to confer immunity against SARS-CoV-2 has been rampant and unprecedented, leading to the emergency clearance of various vaccines. Despite advances in early multidrug therapy for patients with COVID-19, the current mandate is to immunize the world’s population as quickly as possible. The lack of extensive animal testing before clinical trials, and the authorization based on safety data generated in trials that lasted less than 3.5 months, raise questions about the safety of these vaccines. The recently identified role of the SARS-CoV-2 glycoprotein spike which can induce endothelial damage characteristic of COVID-19, even in the absence of infection, is extremely relevant given that most licensed vaccines induce the production of Spike glycoprotein in recipients. Given the high rate of occurrence of adverse reactions and the wide range of types of adverse reactions reported to date, as well as the potential for improvement in vaccine disease, Th2 immunopathology, auto -immunity and immune evasion, there is the need for a better understanding of the benefits and risks of mass vaccination, especially in groups excluded from clinical trials. Despite calls for caution, the risks of SARS-CoV-2 vaccination have been downplayed or ignored by health organizations and government authorities. Given the high rate of occurrence of adverse reactions and the wide range of types of adverse reactions reported to date, as well as the potential for improvement in vaccine disease, Th2 immunopathology, auto -immunity and immune evasion, there is the need for a better understanding of the benefits and risks of mass vaccination, especially in groups excluded from clinical trials. Despite calls for caution, the risks of SARS-CoV-2 vaccination have been downplayed or ignored by health organizations and government authorities. Given the high rate of occurrence of adverse reactions and the wide range of types of adverse reactions reported to date, as well as the potential for improvement in vaccine disease, Th2 immunopathology, auto -immunity and immune evasion, there is the need for a better understanding of the benefits and risks of mass vaccination, especially in groups excluded from clinical trials. Despite calls for caution, the risks of SARS-CoV-2 vaccination have been downplayed or ignored by health organizations and government authorities. of Th2 immunopathology, autoimmunity and immune evasion, there is the need for a better understanding of the benefits and risks of mass vaccination, especially in groups excluded from clinical trials. Despite calls for caution, the risks of SARS-CoV-2 vaccination have been downplayed or ignored by health organizations and government authorities. of Th2 immunopathology, autoimmunity and immune evasion, there is the need for a better understanding of the benefits and risks of mass vaccination, especially in groups excluded from clinical trials. Despite calls for caution, the risks of SARS-CoV-2 vaccination have been downplayed or ignored by health organizations and government authorities. We call for the need for a pluralist dialogue within the framework of health policies.
Introduction
Since the declaration of the Covid-19 pandemic in March 2020, more than 150 million cases and 3 million deaths have been reported worldwide. Despite advances in early outpatient multidrug therapy for high-risk patients, resulting in an 85% reduction in hospitalizations and deaths from COVID-19 [1], the current paradigm of control is mass vaccination . While we recognize the effort involved in the development, production, and emergency authorization of SARS-CoV-2 vaccines, we are concerned that the risks have been minimized or ignored by healthcare organizations. and government authorities, despite cautions [2-8].
Vaccines against other coronaviruses have never been approved for humans, and data generated in the development of coronavirus vaccines designed to elicit neutralizing antibodies shows they may worsen COVID-19 disease via improvement dependent on antibodies (ADE) and Th2 immunopathology, regardless of the vaccine. Platform and delivery method [9-11]. The increase in vaccine-borne illness in animals vaccinated against SARS-CoV and MERS-CoV is known to occur following viral challenge and has been attributed to immune complexes and viral uptake. Fc-mediated by macrophages, which increase T cell activation and inflammation [11 -13].
In March 2020, vaccine immunologists and coronavirus experts assessed the risks of the SARS-CoV-2 vaccine, based on trials of SARS-CoV vaccines in animal models. The expert group concluded that both ADR and immunopathology are a real concern , but said their risk was insufficientto delay clinical trials, although continued monitoring would be necessary [14]. Although there is no clear evidence for the occurrence of ADEs and vaccine-related immunopathology in volunteers immunized with SARS-CoV-2 vaccines [15], safety trials to date no did not specifically address these serious side effects (SAEs). Since the follow-up of the volunteers did not exceed 2-3.5 months after the second dose [16-19], it is unlikely that such an SAE was observed. Despite 92 reporting errors, it cannot be ignored that even taking into account the number of vaccines administered, according to the American Adverse Vaccine Reaction Reporting System (VAERS), the number of deaths per million doses of vaccine administered has multiplied. by more than 10.
In this article, we describe some of the risks of mass vaccination in the context of exclusion criteria for phase 3 trials and discuss the SAE reported in national and regional adverse reaction recording systems. We highlight unanswered questions and draw attention to the need for a more cautious approach to mass immunization. We believe there is an urgent need for an open scientific dialogue on vaccine safety, in the context of large-scale immunization. In this article, we describe some of the risks of mass vaccination in the context of exclusion criteria for phase 3 trials and discuss the SAE reported in national and regional adverse reaction recording systems. We highlight unanswered questions and draw attention to the need for a more cautious approach to mass immunization. We believe there is an urgent need for an open scientific dialogue on vaccine safety in the context of large-scale immunization. In this article, we describe some of the risks of mass vaccination in the context of exclusion criteria for phase 3 trials and discuss the SAE reported in national and regional adverse reaction recording systems. We highlight unanswered questions and draw attention to the need for a more cautious approach to mass immunization. a more cautious approach to mass vaccination. We believe there is an urgent need for an open scientific dialogue on vaccine safety in the context of large-scale immunization. In this article, we describe some of the risks of mass vaccination in the context of exclusion criteria for phase 3 trials and discuss the SAE reported in national and regional adverse reaction recording systems. We highlight unanswered questions and draw attention to the need for a more cautious approach to mass immunization. a more cautious approach to mass vaccination. We believe there is an urgent need for an open scientific dialogue on vaccine safety in the context of large-scale immunization. In this article, we describe some of the risks of mass vaccination in the context of exclusion criteria for phase 3 trials and discuss the SAE reported in national and regional adverse reaction recording systems. We highlight unanswered questions and draw attention to the need for a more cautious approach to mass immunization. we describe some of the risks of mass vaccination in the context of exclusion criteria for phase 3 trials and discuss the SAE reported in national and regional adverse reaction recording systems. We highlight unanswered questions and draw attention to the need for a more cautious approach to mass immunization. we describe some of the risks of mass vaccination in the context of exclusion criteria for phase 3 trials and discuss the SAE reported in national and regional adverse reaction recording systems. We highlight unanswered questions and draw attention to the need for a more cautious approach to mass immunization.
SARS-CoV-2 Phase 3 Trial Exclusion Criteria
With few exceptions, SARS-CoV-2 vaccine trials excluded the elderly [16-19], making it impossible to identify the occurrence of post-vaccination eosinophilia and increased inflammation. in the elderly. Studies with SARS-CoV vaccines have shown that elderly immunized mice are at particularly high risk of potentially fatal Th2 immunopathology [9,20]. Despite this evidence and the extremely limited data on the safety and effectiveness of SARS-CoV-2 vaccines in the elderly, mass vaccination campaigns have focused on this age group from the start. Most trials also excluded pregnant and breastfeeding volunteers, as well as those with
Another exclusion criterion from almost all trials was prior exposure to SARS-CoV-2. This is unfortunate because it removed the possibility of obtaining extremely relevant information regarding post-vaccine adverse reactions in people who already have anti-SARS-Cov-2 antibodies. To the best of our knowledge, EADs are not routinely monitored for any age or group of medical conditions currently receiving the vaccine. In addition, despite a substantial proportion of the population already having antibodies [21], tests to determine the status of anti-SARS-CoV-2 antibodies before vaccine administration are not performed routinely.
Will serious side effects from SARS-CoV-2 vaccines go unnoticed?
COVID-19 encompasses a broad clinical spectrum, ranging from very mild or severe pulmonary pathology, to a fatal multi-organ disease with inflammatory, cardiovascular and even blood coagulation deregulation [22-24]. In this sense, cases of ADR or immunopathology related to the vaccine would be clinically indistinguishable from severe COVID-19 [25]. Additionally, even in the absence of SARS-CoV-2 virus, Spike’s glycoprotein alone causes endothelial damage and hypertension in vitro and in vivo in Syrian hamsters by down-regulating the ACE-converting enzyme. angiotensin 2 (ACE2) and altering mitochondrial function [26]. Although these results need to be confirmed in humans, the implications of this finding are staggering. because all vaccines authorized for emergency use are based on the administration or induction of Spike glycoprotein synthesis. In the case of mRNA vaccines and adenovirus vector vaccines, no studies have examined the duration of Spike production in humans after vaccination.
According to the precautionary principle, it is parsimonious to consider that the synthesis of Spike induced by the vaccine could cause clinical signs of severe COVID-19 and be wrongly counted as new cases of infections with SARS-CoV-2. If so, the true side effects of the current global immunization strategy may never be recognized unless studies specifically examine this issue. There is already non-causal evidence of a temporary or sustained increase in deaths from COVID-19 following vaccination in some countries (Fig. 1). In light of Spike’s pathogenicity, these deaths should be thoroughly investigated to determine if they are related to vaccination. No studies have examined the duration of Spike production in the
Unexpected Adverse Reactions to SARS-CoV-2 Vaccines
Autoimmunity is another critical issue to consider given the global scale of SARS-CoV-2 vaccination. SARS-CoV-2 has many immunogenic proteins, and all but one have similarities to human proteins [27]. These can act as a source of antigens, leading to autoimmunity [28]. While it is true that the same effects could be observed with natural infection with SARS-CoV-2, vaccination is intended for most of the world’s population, while it is estimated that only 10% of the population Global population has been infected with SARS-CoV -2, according to Dr Michael Ryan, head of emergencies at the World Health Organization. We could not find any proof that
Some side effects, including blood clotting disorders, have already been reported in healthy and young vaccinated people. These cases have led to the suspension or cancellation of the use of the adenoviral vector vaccines ChAdOx1-nCov-19 and Janssen in some countries. It has now been proposed that vaccination with ChAdOx1-nCov-19 may result in immune thrombotic thrombocytopenia (VITT) mediated by platelet-activating antibodies against platelet factor-4, which clinically mimics heparin-induced autoimmune thrombocytopenia [29]. Unfortunately, the risk was overlooked when authorizing these vaccines, although adenovirus-induced thrombocytopenia has been known for over a decade and has been a consistent occurrence with adenoviral vectors [30]. The risk of VITT is likely to be higher in people who are already at risk for blood clots.
At the population level, there could also be vaccine-related impacts. SARS-CoV-2 is a rapidly evolving RNA virus, which has so far produced more than 40,000 variants [32,33], some of which affect the antigenic domain of Spike’s glycoprotein [34,35]. Given the high mutation rates, vaccine-induced synthesis of high levels of anti-SARS-CoV-2-Spike antibodies could theoretically lead to suboptimal responses against subsequent infections by other variants in individuals. vaccinated [36], a phenomenon known as “sin” [37] or antigen priming [38]. It is not known to what extent mutations that affect SARS-CoV-2 antigenicity will bind during viral evolution [39], but vaccines could presumably act as selective forces leading to variants with higher infectivity or transmissibility. Given the strong similarity between known variants of SARS-CoV-2, this scenario is unlikely [32,34] but if future variants were to differ further in key epitopes, the global vaccination strategy could have helped shape an even more dangerous virus. This risk was recently brought to the attention of WHO in the form of an open letter [40]. the global vaccination strategy could have helped shape an even more dangerous virus. This risk was recently brought to the attention of WHO in the form of an open letter [40]. the global vaccination strategy could have helped shape an even more dangerous virus. This risk was recently brought to the attention of WHO in the form of an open letter [40].
Discussion
The risks described here constitute a major obstacle to the pursuit of global vaccination against SARS-CoV-2. Evidence of the safety of all SARS-CoV-2 vaccines is needed before more people are exposed to the risk of these experiences, as the release of a candidate vaccine without the time to fully understand the impact that would result on health, could lead to an exacerbation of the current global crisis. [41]. Risk stratification of vaccinees is essential. According to the British government, people under the age of 60 have an extremely low risk of dying from COVID-19. However, according to Eudravigillance, most serious side effects following SARS-CoV-2 vaccination occur in people aged 18 to 64 years. Of particular concern is the planned vaccination schedule for children aged 6 and over in the US and UK. Dr. Anthony Fauci recently predicted that adolescents across the country will be vaccinated in the fall and younger ones in early 2022. Lee UK is awaiting trial results to begin immunizing 11 million under children age 18 to experimental vaccines, given that the Centers for Disease Control and Prevention estimates that they have a 99.997% survival rate if they are infected with SARS-CoV-2. Not only is COVID-19 not relevant as a threat for this age group, there is no reliable evidence to support the efficacy or effectiveness of the vaccine in this population, or to rule out the harmful side effects of these experimental vaccines. In this sense, when physicians advise patients for elective administration of COVID-19 vaccination, there is a great need to better understand the benefits and risks of administration, especially in poorly studied groups.
In conclusion, in the context of the emergency authorization of use of SARS-CoV-2 vaccines, and the current gaps in our understanding of their safety, the following questions need to be raised:
– Is it known whether cross-reacting antibodies from previous coronavirus infections or antibodies induced by the vaccine may influence the risk of unintentional pathogenesis after vaccination with COVID-19?
– Has the specific risk of ADE, immunopathology, autoimmunity and serious adverse reactions been clearly disclosed to vaccine recipients in order to meet the medical ethical standard of patient understanding for the informed consent? If not, what are the reasons and how could it be implemented?
– What is the rationale for administering the vaccine to each individual when the risk of dying from COVID-19 is not equal across age groups and clinical conditions, and when phase 3 trials have excluded individuals elderly, children and frequent specific ailments?
– What are the legal rights of patients if they are injured by a SARS-CoV-2 vaccine? Who will cover the cost of medical treatment? If claims were to be settled with public funds, has the public been made aware that vaccine manufacturers have been granted immunity and that their responsibility for compensating those harmed by the vaccine has shifted to taxpayers?
In the context of these concerns, we propose to put an end to mass vaccination and to open an urgent pluralist, critical and scientifically-based dialogue on SARS-CoV-2 vaccination between scientists, doctors, agencies. international health organizations, regulatory authorities, governments and vaccine developers. This is the only way to bridge the current gap between scientific evidence and public health policy regarding SARS-CoV-2 vaccines. We are convinced that humanity deserves a deeper understanding of the risks than what is currently presented as the official position. An open scientific dialogue is urgent and essential to avoid the erosion of public confidence in science and public health and to ensure that WHO and national health authorities protect the interests of humanity during the current pandemic. There is an urgent need to return public health policy to evidence-based medicine, based on careful assessment of relevant scientific research. It is imperative to follow the science.
Declaration of conflict of interest
The authors state that the research was conducted in the absence of any business or financial relationship that could be interpreted as a potential conflict of interest.
The references
McCullough PA, Alexander PE, Armstrong R et al. Highly targeted multifaceted sequential multidrug therapy for high-risk early ambulatory infection with SARS-CoV-2 (COVID-19). Rev Cardiovasc Med (2020) 21: 517-530. doi: 10.31083 / j.rcm.2020.04.264
Arvin AM, Fink K, Schmid MA, et al. A perspective on the antibody-dependent enhancement of SARS-CoV-2. Nature (2020) 484: 353–363. doi: 10.1038 / s41586-020-2538-8
Coish JM, MacNeil AJ. Out of the pan and into the fire? ADE’s Due Diligence in COVID-19. Infected Microbes (2020) 22 (9): 405-406. doi: 10.1016 / j.micinf.2020.06.006
Eroshenko N, Gill T, Keaveney ML et al. Implications of increased antibody-dependent infection for SARS-CoV-2 countermeasures. Nature Biotechnol (2020) 38: 788–797. doi: 10.1038 / s41587-020-0577-1
Poland GA. Turtles, hares and vaccines: a warning for the development of a vaccine against SARS-CoV-2. Vaccine (2020) 38: 4219–4220. doi: 10.1016 / j.vaccine.2020.04.073
Shibo J. Don’t rush to deploy COVID-19 vaccines and drugs without sufficient security guarantees. Nature (2000) 579 321. doi: 10.1038 / d41586-020-00751-9
Munoz FA, Cramer JP, Dekker CL et al. Enhanced vaccine-associated disease: case definition and guidelines for data collection, analysis and presentation of immunization safety data. Vaccine (2021) https: // doi. org / 10. 1016 / d. vaccine. 2021. 01. 055
Cardozo T, Veazey R. Disclosure of Informed Consent to Vaccine Trial Subjects at Risk of Worsening Clinical Disease from COVID-19 Vaccines. Int J Clin Pract (2020) 28: e13795. doi: 10.1111 / ijcp.13795
Bolles D, Long K, Adnihothram S et al. A double inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces an increased eosinophilic pro-inflammatory pulmonary response upon challenge. J Virol (2001) 85: 12201-12215. doi: 10.1128 / JVI.06048-11
Weingartl H, Czub M, Czub S, et al. Vaccination with modified vaccinia virus Recombinant Ankarab vaccine against severe acute respiratory syndrome is associated with increased hepatitis in ferrets. J Virol (2004) 78: 12672-12676. doi: 10.1128 / JVI.78.22.12672-12676.2004272
Tseng CT, Sbrana E, Iwata-Yoshikawa N, et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology when challenged with SARS virus. PLoS One (2012) 7 (4): e35421. doi: 10.1371 / journal.pone.0035421
Iwasaki A, Yang Y. The potential danger of suboptimal antibody responses in COVID-19. Nat Rev Immunol (2020) 20: 339–341. doi: 10.1038 / s41577-020-0321-6
Vennema H, de Groot RJ, Harbor DA, et al. Early death after challenge with feline infectious peritonitis virus due to immunization with recombinant vaccinia virus. J Virol (1990) 64: 1407-1409
Lambert PH, Ambrosino DM, Andersen SR, et al. Consensus Summary Report for CEPI / BC Meeting March 12-13, 2020: Evaluating the Risk of Disease Improvement with COVID-19 Vaccines. Vaccine (2020) 38 (31): 4783-4791. doi: 10.1016 / j.vaccine.2020.05.064
by Alwis R, Chen S, Gan S et al. Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development. EbioMedicine (2020) 55: 102768. doi: 10.1016 / j.ebiom.2020.102768
Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of ChAdOx1 nCoV vaccine? 287 19 against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet (2020) 396: 467–783. doi: 10.1016 / S0140-6736 (20) 31604-4
Polack FP, Thomas SJ, Kitchin N. Safety and efficacy of BNT162b2 mRNA Covid-19 vaccine. N Engl J Med (2020) 383: 2603-2615. doi: 10.1056 / NEJMoa2034577
Ramasamy MN, Minassian AM, Ewer KJ et al. Safety and Immunogenicity of ChAdOx1 nCoV-19 Vaccine Administered as a First Aid Regimen in Young and Old Adults (COV002): A Phase 2/3 Randomized, Single-Blind Controlled Trial Lancet (2021) 396: 1979–93 . doi: 10.1016 / S0140-6736 (20) 32466-1
Chu L, McPhee R, Huang W et al. MRNA-1273 Study Group. A preliminary report of a phase 2 randomized controlled trial on the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. Vaccine (2021) S0264-410X (21) 00153-5. doi: 10.1016 / j.vaccine.2021.02.007
Liu L, Wei Q, Lin Q et al. Anti-peak IgGs cause severe acute lung damage by skewing macrophage responses during acute SARS-CoV infection. JCI Insight (2019) 4 (4): e123158. doi: 10.1172 / jci.insight.123158.
Ioannidis PA. Death rate from COVID-19 infection inferred from seroprevalence data. Bull WHO (2021) 99: 19–33E. http: // dx. doi. org / 10. 2471 / BLT. 20. 265892
Martines RB, Ritter JM, Matkovic E et al. Pathology and pathogenesis of SARS-CoV-2 associated with fatal coronavirus disease, United States Emerg Infect Dis (2020) 26: 2005-2015. doi: 10.3201 / eid2609.202095
Wu Z, McGoogan JM. Important features and lessons of the 2019 coronavirus disease (COVID-19) outbreak in China: summary of a report of 72,314 cases from the China Center for Disease Control and Prevention. JAMA (2020) 323: 1239-1242. doi: 10.1001 / jama.2020.2648
Xu Z, Shi L, Wang Y et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respiratory Med (2020) 8: 420-422 doi: 10.1016 / S2213-2600 (20) 30076-X
Negro F. Does antibody-dependent enhancement play a role in the pathogenesis of COVID-19? Swiss Medical Weekly (2020) 150: w20249. doi: 10.4414 / smw.2020.20249317
Lei Y, Zhang J, Schiavon CR et al., Spike Protein Empairs Endothelial Function via Downregulation of ACE 2. Circulation Res (2021) 128: 1323–1326. https: // doi. org / 10. 1161 / CIRCRESAHA. 121. 318902
Lyons-Weiler J. Pathogen priming likely contributes to severe and critical illness and mortality from COVID-19 via autoimmunity, J Translational Autoimmunity (2020) 3: 100051. doi: 10.1016 / j.jtauto. 2020.100051
An H, Park J. Molecular Mimicry Map (3M) of SARS-CoV-2: Prediction of potentially immunopathogenic SARS-CoV-2 epitopes via a novel immunoinformatics approach. bioRxiv [Preprint]. November 12, 2020 [cited April 19, 2020] https: // doi. org / 10. 1101/2020. 11. 12. 344424
Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med (2021). doi: 10.1056 / NEJMoa2104840
Othman M, Labelle A, Mazzetti I et al. Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance. Blood (2007) 109: 2832-2839. doi: 10.1182 / sang-2006-06-032524
Ortel TL. Thrombotic risk factors acquired in intensive care. Crit Care Med (2010) 38 (2 Suppl): S43-50. doi: 10.1097 / CCM.0b013e3181c9ccc8
Grubaugh ND, Petrone ME, Holmes EC. We don’t have to worry when a virus mutates during epidemics. Nat Microbiol (2020) 5: 529-530. https: // doi. org / 10. 1038 / s 41 564 – 020 – 0690 – 4
Greaney AJ, Starr TN, Gilchuk P et al. Comprehensive mapping of mutations to the SARS-CoV peak receptor binding domain? 339 2 which escape recognition of antibodies. Cell Host Microbe (2021) 29: 44–57.e9. doi: 10.1016 / j.chom.2020.11.007.
Lauring AS, Hodcroft EB. Genetic Variants of SARS-CoV-2 – What Do They Mean? JAMA (2021) 325: 529-531. doi: 10.1001 / jama.2020.27124
Zhang L, Jackson CB, Mou H et al. The D614G mutation in the SARS-CoV-2 spike protein reduces S1 excretion and increases infectivity. bioRxiv [Preprint]. June 12, 2020 [cited April 19, 2021] https: // doi. org / 10. 1101/2020. 06. 12. 148726
Korber B, Fischer WM, Gnanakaran S et al. Sheffield COVID-19 Genomics Group. Monitoring changes in SARS-CoV-2 peak: evidence that D614G increases the infectivity of the COVID-19 virus. Cell (2020) 182: 812-827.e19. doi: 10.1016 / j.cell.2020.06.043
Francis T. On the doctrine of original antigenic sin. Proc Am Philos Soc (1960) 104: 572-578.
Vibroud C, Epstein SL. The first flu is forever. Science (2016) 354: 706–707. doi: 10.1126 / science.aak9816
Weisblum Y, Schmidt F, Zhang F et al. Escape neutralizing antibodies by spike CoV-2 protein variants of SARS? 354. Elife (2020) 9: e61312. doi: 10.7554 / eLife.61312
Vanden Bossche G (March 6, 2021) https: // dryburgh. com / wp – 356content / uploads / 2021/03 / Geert _ Vanden _ Bossche _ Open _ Letter _ WHO _ March _ 6 _ 2021. pdf
Coish JM, MacNeil AJ. Out of the pan and into the fire? ADE’s Due Diligence in COVID-19. Infected Microbes (2020) 22 (9): 405-406. doi: 10.1016 / j.micinf.2020.06.006
Figure captions
Figure 1. Number of new deaths from COVID-19 compared to the number of people who received at least one dose of vaccine for selected countries. The graph shows data from the start of vaccination to May 3, 365, 2021. A) India (9.25% of the population vaccinated), B) Thailand (1.58% of the population vaccinated), C) Colombia (6 , 79% of the vaccinated population), D) Mongolia (31.65% of the vaccinated population), E) Israel (62.47% of the vaccinated population), F) Worldwide (7.81% of the vaccinated population) ). Charts were constructed using data from Our World in Data (accessed May 4, 2021) https: // github. com / owid / covid – 19 – data / tree / master / public / data / vaccinations
Affiliations
*
1 Epidemiólogos Argentinos Metadisciplinarios. República Argentina.
2 Baylor University Medical Center. Dallas, Texas, United States.
3 Monestir de Sant Benet de Montserrat, Montserrat, Spain
4 INSERM U781 Necker-Enfants Malades Hospital, Paris Descartes-Sorbonne University City, Imagine Institute, Paris, France.
5 School of Natural Sciences. Autonomous University of Querétaro, Querétaro, Mexico.
6 Retired professor of medical immunology. Universidad de Guadalajara, Jalisco, Mexico.
7 Medicos por la Verdad Puerto Rico. Ashford Medical Center. San Juan, Puerto Rico.
8 Retired professor of clinical diagnostic process. University of Murcia, Murcia, Spain
9Urologist Comarcal Hospital of Monforte, University of Santiago de Compostela, Spain.
10 Biólogos por la Verdad, Spain.
11 Retired biologist. University of Barcelona. Specialized in microbiology. Barcelona, Spain.
12 MICAEL Integrative Medicine Center (Medicina Integrativa Centro Antroposófico Educando en Libertad). Mendoza, Argentine Republic.
13 Medicos por la Verdad Argentina. República Argentina. ´
14 Médicos por la Verdad Uruguay. República Oriental del Uruguay.
15 Medicos por la Libertad Chile. República de Chile.
16 Doctor, orthopedist. República de Chile.
17 Medicos por la Verdad Perú. República del Perú.
18Médicos por la Verdad Guatemala. República de Guatemala.
19 Concepto Azul SA Ecuador.
20 Medicos por la Verdad Brasil. Brazil.
21 Medicos por la Verdad Paraguay.
22 Medicines by Costa Rica.
23 Medicos por la Verdad Bolivia.
24 Medicos por la Verdad El Salvador.
* Correspondence: Karina Acevedo-Whitehouse, karina.acevedo.whitehouse@uaq.mx
Author (s): FranceSoir